{"id":942935,"date":"2026-03-09T14:00:02","date_gmt":"2026-03-09T18:00:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/"},"modified":"2026-03-09T14:00:02","modified_gmt":"2026-03-09T18:00:02","slug":"olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/","title":{"rendered":"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA"},"content":{"rendered":"

<\/p>\n

Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA<\/b><\/p>\n

LOS ANGELES–(BUSINESS WIRE<\/a>)–The DJS Law Group<\/a> announces that it is investigating claims on behalf of investors of Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cthe Company\u201d) (NASDAQ: OLMA<\/a>) for violations of the securities laws.<\/p>\n

INVESTIGATION DETAILS: <\/b>The investigation focuses on whether the Company issued misleading statements and\/or failed to disclose information pertinent to investors. Olema is the subject of an Investor\u2019s Business Daily <\/i>report published on March 9, 2026. According to the report, the failure of a Roche trial for an oral breast cancer medication points to issues with Olema\u2019s competing medication. According to analyst Matthew Biegler, the Roche results “comes with a dent to the thesis that oral SERDs can win in front-line breast cancer.” Based on this news, shares of Olema fell by more than 19.6% in morning trading on the same day.<\/p>\n

\nIf you are a shareholder who suffered a loss, contact us to participate<\/a>.<\/p>\n

WHY DJS LAW GROUP?<\/b> DJS Law Group\u2019s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic\/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.<\/p>\n

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260309730374\/en\/<\/a><\/span><\/p>\n

\nDavid J. Schwartz
\n
DJS Law Group
\n
274 White Plains Road, Suite 1
\n
Eastchester, NY 10709
\n
Phone: 914-206-9742
\n
Email: David@djslawllp.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group announces that it is investigating claims on behalf of investors of Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cthe Company\u201d) (NASDAQ: OLMA) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and\/or failed to disclose information pertinent to investors. Olema is the subject of an Investor\u2019s Business Daily report published on March 9, 2026. According to the report, the failure of a Roche trial for an oral breast cancer medication points to issues with Olema\u2019s competing medication. According to analyst Matthew Biegler, the Roche results “comes with … <\/p>\n

Continue reading “Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942935","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOlema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group announces that it is investigating claims on behalf of investors of Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cthe Company\u201d) (NASDAQ: OLMA) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and\/or failed to disclose information pertinent to investors. Olema is the subject of an Investor\u2019s Business Daily report published on March 9, 2026. According to the report, the failure of a Roche trial for an oral breast cancer medication points to issues with Olema\u2019s competing medication. According to analyst Matthew Biegler, the Roche results “comes with … Continue reading "Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T18:00:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309730374r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA\",\"datePublished\":\"2026-03-09T18:00:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/\"},\"wordCount\":324,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260309730374r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/\",\"name\":\"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260309730374r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-03-09T18:00:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260309730374r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260309730374r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/","og_locale":"en_US","og_type":"article","og_title":"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA - Market Newsdesk","og_description":"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group announces that it is investigating claims on behalf of investors of Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cthe Company\u201d) (NASDAQ: OLMA) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and\/or failed to disclose information pertinent to investors. Olema is the subject of an Investor\u2019s Business Daily report published on March 9, 2026. According to the report, the failure of a Roche trial for an oral breast cancer medication points to issues with Olema\u2019s competing medication. According to analyst Matthew Biegler, the Roche results “comes with … Continue reading \"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-09T18:00:02+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309730374r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA","datePublished":"2026-03-09T18:00:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/"},"wordCount":324,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309730374r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/","name":"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309730374r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-03-09T18:00:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309730374r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309730374r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-pharmaceuticals-inc-investigated-on-behalf-of-investors-contact-the-djs-law-group-to-discuss-your-rights-olma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights \u2013 OLMA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942935"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942935\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}